Grant Christian
Cardiovascular Disease · Bountiful, UTNPI 1073671442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Pfizer at 27.8% of the total. Reporting peaked in 2019 at $843 and has fallen 98.4% since, to $14 in 2021. That places this record below the midpoint for cardiovascular disease clinicians in UT, where the typical reported total is $1,352.
Across 91 payments — averaging $11.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$289
- Novartis$101
- Boehringer Ingelheim$98
- AstraZeneca$87
- Merck$74
- Boston Scientific$52
- plus $341 from 15 others
What the payments were for
- Food & beverage$1,041100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $289 |
| Novartis | 8 | $101 |
| Boehringer Ingelheim | 6 | $98 |
| AstraZeneca | 7 | $87 |
| Merck | 5 | $74 |
| Boston Scientific | 3 | $52 |
| Astellas Pharma US Inc | 3 | $45 |
| Novo Nordisk | 3 | $39 |
| Johnson & Johnson | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| AbbVie | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| GE HealthCare | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Amgen | 1 | $15 |
| GSK | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,041 in reported general payments places this provider in the 45th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Bountiful
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
- Divya Ratan VermaMurray$47K
- Daniel VarelaSt George$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.